2019 - Reversible DNA Hypermethylation of the Interleukin-15 (IL-15) Promoter Induces IL-15 Expression, Drives the Pathogenesis of T-Cell Large Granular Lymphocytic Leukemia and Provides a Potential Therapeutic Approach Using 5-Azacitidine. Brammer J.E., Boles A.E., Mansour A., Freud A.G., Mathé-Allainmat M., Quéméner A., Mortier E., Porcu P., and Mishra A. Conference: 61th ASH Annual meeting. Orlando, Florida, USA. Blood 134 (Supplement 1): 3776.

2019 - BTN2A, a New Immune-Checkpoint Targeting Vg9Vd2 T Cell Cytotoxicity. Cano C.E., Pasero C.,De Gassart A., Hoet R., Scotet E., Mortier E., Quéméner A., Rafia C., Briantais A., Le Floch A.-C., and Olive D.   Conference: 61th ASH Annual meeting. Orlando, Florida, USA. Blood 134 (Supplement 1): 1044.

2016 - A novel IL-2 and IL-15 antagonist shifting the immune balance towards tolerance: Potential therapeutic applications‎. Meghnem D., Morisseau S., Trillet K., Frutoso M., Barbieux I., Quéméner A., Jacques Y., and Mortier E. Cancer Immunol. Res. 11:4 ‏ Supplement: ‏ S     Meeting Abstract: ‏ B033.

2016 – Optimization of IL-15-based immunotherapy using an original IL-15 agonist. Frutoso M., Morisseau S., Meghnem D., Khaddage S., Jacques Y., and Mortier E.  Conference: 4th Annual Meeting of The International-Cytokine-and-Interferon-Society (ICIS).  San Francisco, CA, USA.  Cytokine. 87:94. ‏ Meeting Abstract: ‏ P083

2014 - RLI, a sushi-IL-15R alpha/IL-15 fusion protein, is a potent immunomodulatory agent on NK and CD8+T cells and synergizes with anti-PD1 treatment in preclinical mouse tumor models‎. Desbois M., Beal C., Coutzac C., Terme M., Teppaz G., Morisseau S., Béchard D., Mortier E., and Chaput N. Conference: 105th Annual Meeting of the American-Association-for-Cancer-Research (AACR). ‏ San Diego, CA, USA. Cancer Res. 74:19 S Meeting Abstract: ‏ 25.

2011 -  Development of two IL15 immunocytokines targeting either GD2- or CD20-tumoral bearing cells. Vincent M., Teppaz G., Solé V., Bessard A., Loisel S., Watier H., Clémenceau B., Vié H., Birklé S., Garrigue-Antar L., Quéméner A., and Jacques Y.  9th Joint Meeting of the International Society for Interferon and Cytokine Research and the International Cytokine Society. Florence (Italy). Cytokine. 56(1):102.

2010 - Different dynamics of IL-15R activation following IL-15 cis- or trans-presentation‎ . Perdreau H., Mortier E., Bouchaud G., Sole V., Boublik Y., Jacques Y., and Plet A.  Conference: 8th Joint Conference of the International-Cytokine-Society/International-Society-for-and-Cytokine-Research. ‏ Chicago, IL, USA. Cytokine. 52:1-2.

2009 - High antitumor activity of RLI, an IL15-IL15Ralpha fusion protein, in metastatic melanoma and colorectal cancer. Bessard A., Solé V., Bouchaud G., Quéméner A., and Jacques Y.  Annual Meeting of the Society for Leukocyte Biology, International Cytokine Society, & International Society for Interferon and Cytokine Research, Lisbonne (Portugal). Cytokine. 48(1):105.

2008 - The exon 3-encoded domain of IL-15Ralpha contributes to IL-15 high-affinity binding and is crucial for IL-15 antagonistic effect of soluble IL-15Ralpha‎. Bouchaud G., Garrigue-Antar L., Sole V., Quéméner A., Boublik Y., Mortier E., Perdreau H., Jacques Y., and Plet A.  Conference: 7th Joint Conference of the International-Cytokine-Society/International-Society-for-Interferon-and-Cytoklin-Research. Montreal, Canada.  Cytokine. 43:3.

2008 - Release of the soluble alpha chain of IL-15 receptor: a new tumor evasion mechanism associated with poor clinical outcome in head and neck cancer patients‎. Badoual C., Bouchaud G., Agueznay NEH, Mortier E., Hans S., Gey A., Fernani F., Peyrard S., Puig P.L., Bruneval P., Sastre X., Plet A., Garrigue-Antar L., Quintin-Colonna F., Fridman WH, Brasnu D., Jacques Y., and Tartour E. Virchows Arch. 452:S1.

2008 - IL-15 and IL-15 soluble receptor in Crohn's disease active patients before and after infliximab treatment‎. Bourreille A., Bouchaud G., Mortier E., Plet A., Galmiche J.P., and Jacques Y. Gastroenterology.134 :4S1